Verrica Pharmaceuticals (NASDAQ:VRCA) has filed a lawsuit to stop Canadian drugmaker Dormer Labs from selling drugs containing cantharidin in the U.S. In the suit, Verrica has accused Dormer of ...

this week. As part of the agreement, Dormer Labs will stop selling all cantharidin-containing products in the United States, including their Cantharone (Liquid) and Cantharone Plus brands.

Cantharidin: The blister-inducing agent Cantharidin, a chemical applied by healthcare providers, offers another effective treatment option. It causes a blister to form beneath the wart ...

Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a ...

Additionally, there is an anticipation that demand-driven sales will normalize in early 2025, aligning with the discontinuation of compounded cantharidin. Although near-term revenue estimates have ...

a critical mass of previous cantharidin users and strong insurance coverage for YCANTH®. Sales activities in each of these territories will focus on pediatricians in addition to Verrica’s ...

During the first three quarters of 2024, Ycanth recorded sales of $6.3 million. Ycanth, is a proprietary drug-device ...

On October 1, 2024, the Company completed a restructuring of its commercial operations to reduce expenses and optimize the efficiency of its field force by reducing the number of sales territories and ...

Pediatr Infect Dis J. 2008;27(6):551-552. Eczema, also known as atopic dermatitis, is a chronic skin condition which affects 15-20% of the population in developed countries including the United ...

The second part of the study involved inducing a local inflammatory response, using cantharidin, to induce a blister on the forearm of healthy men and women. From this study, Krishnaraj is become ...